Compare Credo Technology Group Holding Ltd (CRDO) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Credo Technology Group Holding Ltd vs IDEXX Laboratories, Inc. — how do they compare? Credo Technology Group Holding Ltd trades at $267.46 (market cap $46.19B), while IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B). The key difference: Credo Technology Group Holding Ltd and IDEXX Laboratories, Inc. are close in size by market cap, and Credo Technology Group Holding Ltd is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| CRDO | IDXX | |
|---|---|---|
Market Cap | $46.19B | $46.22B |
Sector | Technology | Health |
52-Week High | $302.52 | $766.68 |
52-Week Low | $87.81 | $526.44 |
Enterprise Value | $44.77B | $47.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRDO trades at $268.16, up 11.76% in 24 hours, with a bullish technical signal and strong institutional interest. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $1.16 exceeding expectations. Revenue surged to $436.78 million in 2025, and net income margin expanded to 35.37% in 2026. Positive news highlights Credo's role in AI infrastructure, including contributions to the Open Compute Project.
Outlook is positive due to AI-driven demand and strong financials, but risks include premium valuations (P/E 98.68) and customer concentration. Analyst consensus is bullish with a $285.42 price target. Investors should monitor execution risks and market volatility amid high growth expectations.
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Credo Technology Group Holding Ltd
Credo Technology provides high-speed connectivity solutions for AI-driven applications and hyperscale data centers. Its products enable faster, more energy-efficient data transmission for cloud and telecom infrastructure.
Read more on CRDO →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
